Implementation of a restrictive blood transfusion protocol in a gynecologic oncology service.

Blood transfusion Gynecology oncology Gynecologyy Restrictive transfusion

Journal

Gynecology and reproductive endocrinology
ISSN: 2591-7994
Titre abrégé: Gynecol Reprod Endocrinol
Pays: England
ID NLM: 101748772

Informations de publication

Date de publication:
2019
Historique:
entrez: 19 6 2020
pubmed: 1 1 2019
medline: 1 1 2019
Statut: ppublish

Résumé

The purpose of this study was to evaluate the impact of a restrictive blood transfusion protocol in a postoperative gynecologic oncology population. The primary objective was the rate of blood transfusions after surgery before and after implementation of a restrictive transfusion protocol (from July 1 A restrictive blood transfusion protocol was implemented by the gynecologic oncology service at a National Comprehensive Cancer Network designated Comprehensive Cancer Center on January 1 1482 patients were identified for this study (755 in the pre-protocol group and 727 in the post-protocol group). Patients treated under the restrictive protocol had decreased rates of red blood cell transfusion (11.0% A restrictive blood transfusion protocol is associated with reductions in the rates of blood transfusions and postoperative morbidity with a 46.8% reduction in superficial surgical site infection and a 69.6% decrease in deep surgical site infection in the gynecologic oncology patient population.

Identifiants

pubmed: 32550597
doi: 10.35841/2591-7994.3.1-5
pmc: PMC7299237
mid: NIHMS1029689
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1-5

Subventions

Organisme : NCI NIH HHS
ID : T32 CA108456
Pays : United States

Références

Blood. 2009 Apr 9;113(15):3406-17
pubmed: 19188662
Obstet Gynecol Surv. 2015 Dec;70(12):780-92
pubmed: 26676149
JAMA Surg. 2014 Jun;149(6):575-81
pubmed: 24848779
Indian J Anaesth. 2014 Sep;58(5):543-51
pubmed: 25535415
JAMA Surg. 2018 Jan 1;153(1):37-43
pubmed: 28973092
Lancet Haematol. 2016 Dec;3(12):e547
pubmed: 27890071
JAMA. 2016 Nov 15;316(19):2025-2035
pubmed: 27732721
Med Clin North Am. 1993 Mar;77(2):335-47
pubmed: 8441299
Gynecol Oncol. 2015 Jan;136(1):65-70
pubmed: 25451693
Cochrane Database Syst Rev. 2016 Oct 12;10:CD002042
pubmed: 27731885
Am J Obstet Gynecol. 2012 Aug;207(2):94-100
pubmed: 22340944
ISRN Obstet Gynecol. 2013 Aug 12;2013:312982
pubmed: 23997959
N Engl J Med. 1999 Feb 11;340(6):409-17
pubmed: 9971864
Anesthesiology. 2015 Jan;122(1):29-38
pubmed: 25401417
J Pain. 2010 Apr;11(4):330-42
pubmed: 19853526
Gynecol Oncol. 2014 Jan;132(1):227-30
pubmed: 24512847
Fertil Steril. 2014 Oct;102(4):922-32
pubmed: 25274485
J Minim Invasive Gynecol. 2017 Mar - Apr;24(3):402-406
pubmed: 28011096

Auteurs

Jaron Mark (J)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Sarah Lynam (S)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Kayla Morrell (K)

Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, New Tork, USA.

Kevin Eng (K)

Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, New Tork, USA.

Kristen Starbuck (K)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

J Brian Szender (JB)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Emese Zsiros (E)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Peter J Frederick (PJ)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Classifications MeSH